Jubilant Pharmova Limited (NSE:JUBLPHARMA)

Jubilant Pharmova Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Cash & Equivalents	9,564	10,139	9,838	5,020	12,308
Short-Term Investments	-	-	53.53	1,875	1,874
Cash & Short-Term Investments	9,564	10,139	9,892	6,894	14,182
Cash Growth	-5.67%	2.50%	43.48%	-51.39%	2.59%
Accounts Receivable	10,134	10,508	9,914	8,693	13,322
Other Receivables	2,534	1,678	1,497	1,590	2,959
Receivables	12,676	12,197	11,426	10,294	16,442
Inventory	13,038	14,215	12,861	11,429	18,792
Prepaid Expenses	910	900	833.54	823.74	741.59
Other Current Assets	2,573	173	79.99	84.63	225.82
Total Current Assets	38,761	37,624	35,092	29,525	50,383
Property, Plant & Equipment	36,871	33,652	27,911	25,752	42,875
Long-Term Investments	422	2,564	2,386	2,541	693.64
Goodwill	24,639	24,286	22,428	21,300	20,895
Other Intangible Assets	10,433	9,510	9,263	8,006	7,314
Long-Term Deferred Tax Assets	2,327	2,275	1,613	1,547	2,112
Other Long-Term Assets	2,029	1,652	1,211	504.39	765.6
Total Assets	115,485	111,567	99,909	89,181	125,217
Accounts Payable	8,563	8,213	5,677	5,205	10,903
Accrued Expenses	3,293	2,786	3,091	2,846	3,407
Short-Term Debt	1,965	2,583	640	200.01	6,499
Current Portion of Long-Term Debt	505	414	3,994	-	2,386
Current Portion of Leases	521	534	521.93	501.34	440.48
Current Income Taxes Payable	370	624	345.06	468.11	1,059
Current Unearned Revenue	998	719	909.81	544.6	630.75
Other Current Liabilities	2,675	1,851	737.41	722.98	865.15
Total Current Liabilities	18,890	17,724	15,916	10,488	26,190
Long-Term Debt	31,671	31,104	24,642	25,640	37,397
Long-Term Leases	1,978	2,133	2,122	1,955	1,361
Long-Term Unearned Revenue	5,438	2,685	72.96	75.71	82.9
Long-Term Deferred Tax Liabilities	2,108	3,062	3,030	2,473	2,634
Other Long-Term Liabilities	647	459	445.45	602.28	380.92
Total Liabilities	61,274	57,649	46,745	41,766	69,178
Common Stock	158	159	159.28	159.28	159.28
Additional Paid-In Capital	-	-	-	-	5,873
Retained Earnings	45,397	45,368	46,860	43,187	45,852
Comprehensive Income & Other	8,784	8,466	6,166	4,069	4,155
Total Common Equity	54,339	53,993	53,186	47,415	56,039
Minority Interest	-128	-75	-21.63	0.31	-
Shareholders' Equity	54,211	53,918	53,164	47,415	56,039
Total Liabilities & Equity	115,485	111,567	99,909	89,181	125,217
Total Debt	36,640	36,768	31,920	28,296	48,084
Net Cash (Debt)	-27,076	-26,629	-22,028	-21,401	-33,902
Net Cash Per Share	-170.44	-167.32	-138.39	-134.37	-212.85
Filing Date Shares Outstanding	158.35	159.07	159.17	159.17	159.28
Total Common Shares Outstanding	158.35	159.07	159.17	159.17	159.28
Working Capital	19,871	19,900	19,176	19,037	24,193
Book Value Per Share	343.16	339.43	334.14	297.88	351.82
Tangible Book Value	19,267	20,197	21,495	18,109	27,830
Tangible Book Value Per Share	121.67	126.97	135.04	113.77	174.72
Land	444	440	447.86	436.86	619.36
Buildings	8,622	8,498	7,957	7,744	10,801
Machinery	32,484	29,213	26,009	21,826	38,223
Construction In Progress	12,523	7,733	2,918	2,778	2,636

Source: S&P Global Market Intelligence. Standard template. Financial Sources.